A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Public ClinicalTrials.gov record NCT06101134. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma
Study identification
- NCT ID
- NCT06101134
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- relatlimab+nivolumab Drug
- relatlimab+nivolumab+rHuPH20 Drug
- nivolumab Drug
- nivolumab+rHuPH20 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2023
- Primary completion
- Apr 9, 2025
- Completion
- Aug 30, 2027
- Last update posted
- Apr 8, 2026
2023 – 2027
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0007 | Anchorage | Alaska | 99508-2974 | — |
| Local Institution - 0013 | Phoenix | Arizona | 85054-4502 | — |
| Local Institution - 0010 | San Francisco | California | 94115-3010 | — |
| Local Institution - 0034 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0032 | Edgewood | Kentucky | 41017 | — |
| Local Institution - 0028 | Albuquerque | New Mexico | 87106 | — |
| Local Institution - 0037 | Edmonds | Washington | 98026-8032 | — |
| Local Institution - 0036 | Issaquah | Washington | 98026 | — |
| Local Institution - 0030 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06101134, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06101134 live on ClinicalTrials.gov.